BioLargo, Inc. develops and commercializes sustainable technologies across cleantech, environmental engineering, water treatment and life sciences. Company updates commonly cover its Aqueous Electrostatic Concentrator, a PFAS treatment technology designed to remove and collect per- and polyfluoroalkyl substances from liquid streams, as well as engineering services and project work in water, wastewater, remediation and minerals processing.
BioLargo news also follows subsidiary activity, including Clyra Medical Technologies and its FDA-cleared wound care products based on Copper-Iodine Complex Technology, distribution partnerships for ViaCLYR, investor communications, annual operating results, and commercialization updates across medical, environmental and battery-related business lines.
BioLargo (OTCQX:BLGO) announced the formation of subsidiary BioLargo CPG to relaunch CupriDyne®-based consumer pet products under a new, yet-to-be-named brand. The move follows the marketing success of CupriDyne products previously licensed to Pooph, which generated more than $125 million in pet-care sales.
BioLargo plans a digital-first strategy, selling direct-to-consumer and via online marketplaces such as Amazon, and intends to expand from pet odor control into broader household odor and cleaning products. According to Grand View Research, the U.S. pet odor control and clean-up market was about $6.47 billion in 2023, projected to reach $8.87 billion by 2030. Management highlights that BioLargo will now own the brand and control marketing and distribution.
BioLargo (OTCQX:BLGO) announced that its engineering unit, BioLargo Engineering, Science & Technologies (BLEST), received $1.4 million in U.S. Air Force contract renewals over 12 months. The contracts extend multi-year air quality and environmental compliance work at five Air Force bases in New Mexico and Arizona.
BLEST continues as a subcontractor, providing regulatory compliance, permitting, testing, air data management, reporting, and inventory management. According to BioLargo, these recurring contracts support a base of repeatable engineering revenue alongside larger projects and product sales.
BioLargo (OTCQX: BLGO) subsidiary Clyra Medical signed an exclusive distribution agreement with Al-Hikma FZCO to commercialize ViaCLYR™ across the Gulf Cooperation Council, the Levant, North Africa, and adjacent markets. The deal includes territory exclusivity tied to performance and cooperative country-level regulatory work is underway.
ViaCLYR™ uses Clyra's Clyrasept™ Copper-Iodine Complex Solution (CICS) as a broad-spectrum antimicrobial for wound irrigation. The partners plan coordinated regulatory filings and commercial rollout across a region serving over 500 million people.
BioLargo (OTCQX:BLGO) signed a non-exclusive memorandum of understanding with Aquatech on May 4, 2026 to advance commercialization of BioLargo's Aqueous Electrostatic Concentrator (AEC) for PFAS treatment.
AEC concentrates and immobilizes PFAS onto membranes without producing a secondary concentrated liquid waste stream; the MOU targets integration of AEC as a concentration and collection step within Aquatech's end-to-end PFAS flowsheets worldwide.
BioLargo (OTCQX: BLGO) announced CEO Dennis P. Calvert will participate in a town hall on May 5, 2026 at 1:00 PM PT on the BioLargo Shareholder Community Discord. The meeting will include a brief company update and shareholder Q&A.
The meeting will be recorded and a transcript will be filed on Form 8-K before market open the following day. Shareholders may pre-submit questions via the Reddit announcement and are encouraged to join the Discord in advance.
BioLargo (OTCQX:BLGO) announced that BioLargo Engineering, Science & Technologies won a $1.2 million contract to design a pilot-scale minerals processing facility to remediate and repurpose a legacy mineral waste deposit in the western United States.
The design phase will take approximately six months; the overall program could progress to full-scale commercial production over an approximate two- to three-year timeframe, subject to successful pilot results and milestone approvals.
BioLargo (OTCQX:BLGO) will sponsor and participate in a PFAS legal and technical forum on April 29, 2026 in Mineola, NY. CEO Dennis P. Calvert and BEST President Tonya Chandler will present the Global Environmental Leadership Award to Robert Bilott and join a technical panel.
BioLargo will feature its AEC (Aqueous Electrostatic Concentrator) technology, described as removing PFAS from water without generating secondary waste streams, and will sponsor a private screening of the film "Revealed: How to Poison a Planet."
BioLargo (OTCQX:BLGO) reported 2025 annual results showing mixed operational progress and significant financial headwinds. Revenues fell to $7.765M from $17.779M in 2024 while net loss widened to $15.189M. The company ended 2025 with $3.883M cash and total assets of $8.311M versus liabilities of $6.785M.
Operational highlights included 98% growth in third‑party engineering services, subsidiary capital raises for Clyra and Cellinity, a first stocking order for ViaCLYR, and PFAS treatment installations.
BioLargo (OTCQX: BLGO) will host an investor webcast and conference call on Thursday, March 5, 2026 at 12:00 PM ET (9:00 AM PT) to review financial results for the quarter ended December 31, 2025, discuss recent milestones, and hold a Q&A session.
Live access requires registration at the webcast link at least 15 minutes before start; replay will be available through March 19, 2026 with provided passcode.
BioLargo (OTCQX:BLGO) announced that Dr. Marcus Gitterle presented multi-site clinical experience with ViaCLYR at the Boswick Symposium on January 28, 2026. The ~36-case evaluation across four clinics showed rapid wound fluid reduction, enhanced healing, strong antimicrobial activity, tunnel closure, and no reported adverse events.
Clyra's Copper-Iodine Complex Solution (Clyrasept) was cited as the active technology behind observed tissue improvements and increased adoption by participating clinicians.